Ambu A/S (OTCMKTS:AMBBY) Downgraded by UBS Group to Hold

Ambu A/S (OTCMKTS:AMBBY) was downgraded by equities research analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks reports.

Ambu A/S Price Performance

Ambu A/S stock opened at $10.25 on Tuesday. The firm has a market capitalization of $2.41 billion, a PE ratio of 34.17 and a beta of 0.93. Ambu A/S has a 52 week low of $8.54 and a 52 week high of $16.78. The firm’s 50-day simple moving average is $10.73 and its 200 day simple moving average is $10.46. The company has a quick ratio of 1.73, a current ratio of 2.92 and a debt-to-equity ratio of 0.08.

Ambu A/S (OTCMKTS:AMBBY) last posted its earnings results on Tuesday, August 25th. The company reported $0.09 earnings per share for the quarter. Ambu A/S had a net margin of 8.18% and a return on equity of 8.56%. The firm had revenue of $255.12 million during the quarter.

Ambu A/S Company Profile

Ambu A/S is a Danish medical technology company that develops, manufactures and markets single-use devices for hospitals and other healthcare providers. The company focuses on reducing the need to reprocess reusable equipment while supporting clinical procedures in areas such as endoscopy, anesthesia and patient monitoring.

Ambu’s product portfolio includes disposable endoscopes and related visualization systems, airway management products, anesthesia equipment and devices used for patient monitoring and diagnostics.